Pharmacokinetics (PK) of indacaterol acetate and mometasone furoate delivered alone or in combination following once daily inhalation in healthy subjects Source: International Congress 2014 – Asthma and COPD management Year: 2014
Pharmacokinetics (PK), safety and tolerability of abediterol and mometasone furoate fixed- and free-dose combinations in healthy subjects Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
Efficiency of once-daily mometasone furoate in school children with seasonal allergic rhinitis and severe nasal congestion Source: Eur Respir J 2006; 28: Suppl. 50, 664s Year: 2006
Pharmacokinetics (PK) of mometasone furoate and indacaterol in Japanese and Caucasian healthy subjects after once daily inhalation of QMF149 Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Mometasone furoate delivered via the Breezhaler® and Twisthaler® devices in asthma Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
Mometasone furoate nasal spray compared with loradatine in school children with seasonal allergic rhinitis Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Assessment of the defined daily dose for mometasone furoate dry powder inhaler in persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Evaluation of fluticasone (flixonase) nasal spray versus beclomethasone (beconase) nasal spray in the treatment of allergic rhinitis Source: Eur Respir J 2004; 24: Suppl. 48, 124s Year: 2004
Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
QAV680, cetirizine and their combination reduce nasal symptoms in patients with intermittent allergic rhinitis in an environmental exposure chamber Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
Efficacy of mometasone furoate in patients with mild-to-moderate asthma: lack of gender-specific effects Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
Effects of mometasone furoate dry powder inhaler administered once-daily in the evening on symptom control in mild to moderate asthma Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003
Efficacy and safety of 10 day treatment with the CRTh2 antagonist QAV680 evaluated in patients with allergic rhinitis in an environmental exposure chamber Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
A comparison of fluticasone propionate (FP) and mometasone furoate (MF) nasal spray in the treatment of nasal polyposis associated with asthma Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006
Comparative efficacy and safety of mometasone furoate dry powder inhaler and budesonide Turbuhaler(R) Source: Eur Respir J 2001; 17: 1332-1333 Year: 2001
Comparative efficacy of different groups of drugs for the treatment of bronchial asthma in combination with allergic rhinitis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014
Once-daily, evening administration of mometasone furoate dry powder inhaler improves pulmonary function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003
Intranasal GSK2245035 induces prolonged reductions in nasal responsiveness to allergen Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015
Administration of mometasone furoate once daily in the evening is as effective as mometasone furoate administered twice daily in improving lung function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003